middle.news
Dimerix Bolsters Kidney Disease Pipeline with Phase 2-Ready AKI Drug DMX-652 Acquisition
9:03am on Friday 17th of July, 2026 AEST
•
Biotechnology
Read Story
Dimerix Bolsters Kidney Disease Pipeline with Phase 2-Ready AKI Drug DMX-652 Acquisition
9:03am on Friday 17th of July, 2026 AEST
Key Points
Acquisition of DMX-652 expands pipeline into acute kidney injury
Phase 2 trial approved by FDA, dosing expected in H1 2027
Strong Phase 1 safety data with no serious adverse events
Potential $3.5 billion global market opportunity by 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE